Pharming Group N.V. - ADR Forecast, price target & analysts
Pharming Group N.V. - ADR Target price 2026 - Analyst rating & recommendation
Pharming Group N.V. - ADR Classifications & Recommendation
Pharming Group N.V. - ADR Price Target
| Target Price | $2.34 |
| Price | $10.55 |
| Deviation |
77.79%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Pharming Group N.V. - ADR 2027 .
The average Pharming Group N.V. - ADR target price is $2.34.
This is
77.79%
register free of charge
$2.90
72.56%
register free of charge
$2.09
80.20%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Pharming Group N.V. - ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2027 of
77.79%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 376.13 | 408.22 |
| 26.56% | 8.53% | |
| EBITDA Margin | 11.56% | 7.52% |
| 361.15% | 34.95% | |
| Net Margin | 0.76% | 7.44% |
| 119.02% | 881.90% |
7 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2026 . The average Pharming Group N.V. - ADR sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2026. The average Pharming Group N.V. - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Pharming Group N.V. - ADR Analysts have issued a net profit forecast 2026. The average Pharming Group N.V. - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.00 | 0.04 |
| 100.00% | ||
| P/E | 245.81 | |
| EV/Sales | 1.76 |
8 Analysts have issued a Pharming Group N.V. - ADR forecast for earnings per share. The average Pharming Group N.V. - ADR EPS is
This results in the following potential growth metrics and future valuations:
Pharming Group N.V. - ADR...
Current Pharming Group N.V. - ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jul 12 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | May 07 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 29 2026 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Feb 25 2026 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Feb 04 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Feb 03 2026 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jan 21 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Jul 12 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
May 07 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 29 2026 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Feb 25 2026 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Feb 04 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Feb 03 2026 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Jan 21 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
